|Bid||249.75 x 500|
|Ask||254.70 x 100|
|Day's Range||249.01 - 251.00|
|52 Week Range||223.02 - 333.65|
|PE Ratio (TTM)||15.66|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The trial enrolled 1,313 RMS patients in 21 countries for two years of study.
Biogen isn't a bad biotech stock pick. But Celgene is better. Here's why.
Regeneron, Vertex and Alexion look likely to catch the next wave in biotech and start a boom, an analyst says.